Suppr超能文献

偏头痛与缺血性心脑血管疾病(CCVD)的关联,以及曲普坦类和麦角胺类药物对韩国 NHIS-HEALS 队列中偏头痛患者缺血性 CCVD 风险的影响。

Association Between Migraine and Ischemic Cardio-Cerebrovascular Disease (CCVD) and Effects of Triptans and Ergotamine on the Risk of Ischemic CCVD in Patients with Migraine in the Korean NHIS-HEALS Cohort.

机构信息

Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.

Department of Information and Statistics, Chungbuk National University, Cheongju, Republic of Korea.

出版信息

Clin Drug Investig. 2023 Jul;43(7):541-550. doi: 10.1007/s40261-023-01290-7. Epub 2023 Jul 17.

Abstract

BACKGROUND AND OBJECTIVES

Triptans and ergotamine are commonly used to treat migraine, a risk factor for ischemic stroke. This study aimed to investigate the association between migraine and ischemic cardio-cerebrovascular disease (CCVD). Further analyses were performed to examine whether symptom-relieving treatment of migraine with triptans and ergotamine reduces ischemic CCVD in migraineurs.

METHODS

Participants from the Korean NHIS-HEALS cohort database were divided into patients reporting headache without migraine (HA), migraineurs who received at least one prescription for triptans or ergotamine (TE), and migraineurs who were prescribed neither triptans nor ergotamine (NTNE). Ischemic CCVDs comprised ischemic cerebrovascular diseases and cardiovascular diseases. Using cox proportional hazards regression models, primary and secondary analysis for risk of ischemic CCVDs was compared.

RESULTS

Among 62,272 patients diagnosed with migraine or HA, men with migraine or HA numbered 14,747 and 8935, respectively, while the numbers of women were 27,836 and 10,754, respectively. The median follow-up was 6.65 years. The overall incidence rate of CCVDs was 4728/38,590 (12.25%) in females and 3158/23,682 (13.33%) in males. Compared with the HA group, the hazard ratios (HRs) (95% CIs) of the TE and NTNE groups for ischemic CCVDs were 1.18 (1.01-1.39) and 1.39 (1.28-1.50), respectively, in males, and 1.22 (1.09-1.37) and 1.53 (1.42-1.65), respectively, in females, after full adjustment for confounding variables. Compared with the NTNE group, the HRs (95% CIs) of the TE group for ischemic CCVDs were 0.86 (0.73-0.999) in males and 0.80 (0.72-0.88) in females.

CONCLUSIONS

Migraine increased the risk of ischemic CCVDs in both sexes, and migraineurs treated with triptans and ergotamine were at lower risk of ischemic CCVDs than migraineurs who did not take those medications, especially in women.

摘要

背景与目的

曲坦类药物和麦角胺常用于治疗偏头痛,而偏头痛是缺血性卒中等心脑血管疾病的一个危险因素。本研究旨在探讨偏头痛与缺血性心脑血管疾病(CCVD)之间的关系。进一步分析旨在研究偏头痛患者使用曲坦类药物和麦角胺缓解症状治疗是否会降低偏头痛患者的缺血性 CCVD 风险。

方法

本研究使用了韩国 NHIS-HEALS 队列数据库中的参与者,将报告头痛但无偏头痛(HA)的患者分为无偏头痛组(HA)、至少接受过一次曲坦类药物或麦角胺治疗的偏头痛患者组(TE)和既未接受过曲坦类药物也未接受过麦角胺治疗的偏头痛患者组(NTNE)。缺血性 CCVD 包括缺血性脑血管病和心血管疾病。使用 Cox 比例风险回归模型,比较了原发性和继发性缺血性 CCVD 风险。

结果

在 62272 名被诊断为偏头痛或 HA 的患者中,男性偏头痛或 HA 患者人数分别为 14747 人和 8935 人,而女性偏头痛或 HA 患者人数分别为 27836 人和 10754 人。中位随访时间为 6.65 年。女性 CCVD 的总体发生率为 4728/38590(12.25%),男性为 3158/23682(13.33%)。与 HA 组相比,TE 组和 NTNE 组男性缺血性 CCVD 的风险比(HR)(95%CI)分别为 1.18(1.01-1.39)和 1.39(1.28-1.50),女性分别为 1.22(1.09-1.37)和 1.53(1.42-1.65),校正了混杂因素后。与 NTNE 组相比,TE 组男性缺血性 CCVD 的 HR(95%CI)为 0.86(0.73-0.999),女性为 0.80(0.72-0.88)。

结论

偏头痛增加了两性缺血性 CCVD 的风险,与未使用曲坦类药物和麦角胺治疗的偏头痛患者相比,使用曲坦类药物和麦角胺治疗的偏头痛患者缺血性 CCVD 的风险较低,尤其是女性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验